» Articles » PMID: 36820641

SARS-CoV-2 Molecular Epidemiology in Slovenia, January to September 2021

Abstract

BackgroundSequencing of SARS-CoV-2 PCR-positive samples was introduced in Slovenia in January 2021. Our surveillance programme comprised three complementary schemes: (A) non-targeted sequencing of at least 10% of samples, (B) sequencing of samples positive after PCR screening for variants of concern (VOC) and (C) sequencing as per epidemiological indication.AimWe present the analysis of cumulative data of the non-targeted surveillance of SARS-CoV-2 and variant-dependent growth kinetics for the five most common variants in Slovenia for the first 9 months of 2021.MethodsSARS-CoV-2 PCR-positive samples, from January to September 2021, were selected for sequencing according to the national surveillance plan. Growth kinetics studies were done on Vero E6 cells.ResultsAltogether 15,175 genomes were sequenced and 64 variants were detected, of which three successively prevailed. Variant B.1.258.17 was detected in ca 80% of samples in January and was replaced, within 9 weeks, by the Alpha variant. The number of cases decreased substantially during the summer of 2021. However, the introduction of the Delta variant caused a fourth wave and completely outcompeted other variants. Other VOC were only detected in small numbers. Infection of Vero E6 cells showed higher replication rates for the variants Alpha and Delta, compared with B.1.258.17, B.1.258, and B.1.1.70, which dominated in Slovenia before the introduction of the Alpha and Delta variants.ConclusionInformation on SARS-CoV-2 variant diversity provided context to the epidemiological data of PCR-positive cases, contributed to control of the initial spread of known VOC and influenced epidemiological measures.

Citing Articles

The Influence of COVID-19 on Antimicrobial Resistance Trends at a Secondary Care Hospital in Slovenia: An Interrupted Time Series Analysis.

Jeverica S, Maganja D, Dernic J, Golob P, Stepisnik A, Novak B Antibiotics (Basel). 2024; 13(11).

PMID: 39596728 PMC: 11590949. DOI: 10.3390/antibiotics13111033.


Genetic variability in the glucocorticoid pathway and treatment outcomes in hospitalized patients with COVID-19: a pilot study.

Stampar P, Blagus T, Goricar K, Bogovic P, Turel G, Strle F Front Pharmacol. 2024; 15:1418567.

PMID: 39135792 PMC: 11317398. DOI: 10.3389/fphar.2024.1418567.

References
1.
Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N . Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. Euro Surveill. 2021; 26(24). PMC: 8212592. DOI: 10.2807/1560-7917.ES.2021.26.24.2100509. View

2.
Radvak P, Kwon H, Kosikova M, Ortega-Rodriguez U, Xiang R, Phue J . SARS-CoV-2 B.1.1.7 (alpha) and B.1.351 (beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains. Nat Commun. 2021; 12(1):6559. PMC: 8589842. DOI: 10.1038/s41467-021-26803-w. View

3.
van Kampen J, van de Vijver D, Fraaij P, Haagmans B, Lamers M, Okba N . Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). Nat Commun. 2021; 12(1):267. PMC: 7801729. DOI: 10.1038/s41467-020-20568-4. View

4.
Corman V, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu D . Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020; 25(3). PMC: 6988269. DOI: 10.2807/1560-7917.ES.2020.25.3.2000045. View

5.
Challen R, Brooks-Pollock E, Read J, Dyson L, Tsaneva-Atanasova K, Danon L . Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021; 372:n579. PMC: 7941603. DOI: 10.1136/bmj.n579. View